Free tool
FAERS Monitor: Atropen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017106 or its brand name (Atropen, Atropine). Reports on generic versions are filed under their own applications.
Reports
8,429
Serious
7,748
92% of reports
Hospitalization
3,586
Death reported
1,634
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective634
- off label use595
- diarrhoea591
- fatigue538
- nausea522
- hypotension506
- death460
- dyspnoea436
- bradycardia399
- pain394
- vomiting375
- cardiac arrest315
- toxicity to various agents301
- pyrexia293
- constipation276
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 194 |
| 2005 | 156 |
| 2006 | 170 |
| 2007 | 108 |
| 2008 | 168 |
| 2009 | 177 |
| 2010 | 174 |
| 2011 | 318 |
| 2012 | 509 |
| 2013 | 223 |
| 2014 | 241 |
| 2015 | 388 |
| 2016 | 405 |
| 2017 | 367 |
| 2018 | 462 |
| 2019 | 509 |
| 2020 | 569 |
| 2021 | 555 |
| 2022 | 542 |
| 2023 | 592 |
| 2024 | 555 |
| 2025 | 513 |
| 2026 | 531 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,730 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bradycardiaSignal | 399 | 18.9 | 17.2 | 6,718 |
| cardiac arrestSignal | 315 | 9.6 | 8.6 | 2,404 |
| hypotensionSignal | 506 | 6.3 | 5.8 | 2,271 |
| toxicity to various agentsSignal | 301 | 4.5 | 4.0 | 810 |
| constipationSignal | 276 | 3.2 | 2.8 | 409 |
| diarrhoeaSignal | 591 | 2.3 | 2.1 | 439 |
| pyrexiaSignal | 293 | 2.1 | 1.9 | 174 |
| vomiting | 375 | 2.0 | 1.8 | 188 |
| dyspnoea | 436 | 1.9 | 1.8 | 197 |
| fatigue | 538 | 1.7 | 1.6 | 169 |
| off label use | 595 | 1.7 | 1.6 | 177 |
| nausea | 522 | 1.6 | 1.5 | 137 |
| pain | 394 | 1.6 | 1.5 | 91 |
| death | 460 | 1.3 | 1.2 | 39 |
| drug ineffective | 634 | 1.2 | 1.1 | 22 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.